Skip to main content
Equibles
MGNX logo

MGNX · Macrogenics Inc

Track MGNX — free

Use MGNX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MGNX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.06 -0.02 (-0.37%)
Market Cap
$265.63M
Shares
63.70M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.07 Open$4.14 Day$4.02–4.19 52W close$1.33–4.86 Avg vol 30d709K Short int7.3M · 11.5% float · 9.3d Short vol68% Last earningsMay 20, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 14

Up next

Next earnings call
Sep 10, 2026 Est · unconfirmed · in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +42%
above
Price vs 50-day avg −4%
below
RSI (14) 50
neutral
MACD trend Positive
52-week position 78%
mid-range
Momentum
relative strength
Very Strong
1-month return +2%
trailing
6-month return +105%
trailing
YTD return +153%
this year
Relative strength +93%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.52% of float · ▲ +29.0% MoM · 9.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
121 holders — mid 3-yr range
Squeeze score 68
elevated · 0–100
Fundamentals
Weak
Revenue growth −0%
Y/Y
EPS growth −10%
Y/Y
Free cash flow $-83.0M
Balance sheet $57.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 90%
annualized · 1-yr
Max drawdown −34%
past year
ATR 6.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+42% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
50 Neutral
MACD trend
Positive Bullish
52-week position
78% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.52% of float · ▲ +29.0% MoM · 9.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
121 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $4 · 78% Range high $5
vs 200-day avg +42% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
employees expected at closing 135 Q1 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MGNX
Macrogenics Inc
this stock
$265.63M +152.8% -0.3% — 11.5%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
121
% held
76.6%
Net QoQ
+5.4M sh
Top holder
ARMISTICE CAPITAL, LLC
Held Float
View
Held by Funds
Fund positions
55
View
Short & Settlement
Short Interest Rising
Shares short
7.3M
Days to cover
9.3d
Change
+1.6M sh
View
Short Volume
Short vol %
68%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
7.1K
Value
$26.1K
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
26.0%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$149.5M
Net income (FY)
$-74.6M
EPS diluted
$-1.18
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
16
View
Proposed Sales
Value
$798.8K
Shares
51.4K
Filed
Apr 4, 2024
View
Earnings & Events
Earnings Calls
Last call
May 20, 2026
View
Investor Relations
Latest news
MacroGenics Reports Second Quarte…
Published
Aug 13, 2026
View

Performance

5D 20D 120D MTD YTD
MGNX -0.3% +1.5% +104.5% +10.3% +152.8%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY +1.7% -1.8% +93.4% +8.2% +141.0%
Key facts CIK 1125345 CUSIP 556099109 13F (30d) 122 filings 119 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)